Last reviewed · How we verify
NCT05724004: A-SAB
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
NA trial testing SBRT/SRS/radiation therapy in Radiotherapy Side Effect in 70 participants. Currently enrolling.
20 June 2024
Quick facts
| Lead sponsor | Karolinska University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 5 October 2023 |
| Primary completion | 20 June 2024 |
| Estimated completion | 20 June 2031 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- SBRT/SRS/radiation therapy
Conditions studied
- Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- ALK Gene Mutation — all drugs for ALK Gene Mutation →
Sponsor
Karolinska University Hospital
Who can join
20 and older, any sex, with Radiotherapy Side Effect or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn evaluate the safety and efficacy of the addition of radiation therapy to all tumour lesions, to first line medical treatment with alectinib in non-small cell lung cancer harbouring ALK-rearrangements. The main aims of the trial are to evaluate: * if the treatment combination is safe * if the treatment combination can inhibit progression Participants who have responded to 1st line alectinib will be treated with consolidation radiation therapy to all remaining tumour lesions while continuing on alectinib until disease progression, unacceptable toxicity or another discontinuation criterion is met.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms Underlying Radioresistance and Reversal Strategies in Non-Small Cell Lung Cancer.
Zhao C, Luo S, Shao Q, Li P, et al · · 2025 · cited 4× · PMID 40724808 · DOI 10.3390/ijms26146559
Verify or expand the search:
- PubMed search for NCT05724004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiotherapy Side Effect
Currently open trials in the same condition.
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
- NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
- NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
- NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
Other Karolinska University Hospital trials
Trials by the same sponsor.
- NCT07424690 — Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation · NA · not yet recruiting
- NCT06639191 — [177Lu]Lu-AKIR001 First-in-human Study · EARLY_PHASE1 · recruiting
- NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
- NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
- NCT06835816 — Amino Acid Supplementation in Continuous Renal Replacement Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05724004 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karolinska University Hospital
- Last refreshed: 10 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing